Analyst Price Targets — CS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2022 10:00 am | — | Industrial Alliance Securities | $12.00 | $5.80 | Benzinga | Credit Suisse Initiates Coverage On Full Truck Alliance Co with Outperform Rating, Announces Price Target of $12 |
| May 20, 2022 6:43 am | — | Credit Suisse | $12.00 | $6.75 | Benzinga | Credit Suisse Assumes Diversey Hldgs at Outperform, Announces Price Target of $12 |
| May 12, 2022 6:34 am | — | Credit Suisse | $14.00 | $6.20 | Benzinga | Credit Suisse Upgrades Plains GP Holdings to Outperform, Raises Price Target to $14 |
Latest News for CS
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and has received FDA Breakthrough Therapy Designation for CS Global Phase 3 study (BEACON+) is underway, evaluating brepocitinib 45 mg once daily against placebo in 140 patients across approximately 70…
Alcon Launches UNITY® CS at COS 2026, Advancing the Next Generation of Surgical Innovation in Canada
MONTRÉAL--(BUSINESS WIRE)--Alcon announces the launch and Canadian availability of UNITY® Cataract System (CS), Alcon's next-generation standalone cataract surgical platform.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CS.
Senate Trading
No Senate trades found for CS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.